Contrasting hemodynamic mechanisms of losartan- vs. atenolol-based antihypertensive treatment: A LIFE study

American Journal of Hypertension

Volumn 25, Issue 9, 2012, Pages 1017-1023

  Greve, Anders M ^a   Olsen, Michael H ^b   Bella, Jonathan N ^c   Lønnebakken, Mai T ^d,e   Gerdts, Eva ^d,e   Okin, Peter M ^c   Palmieri, Vittorio ^c   Boman, Kurt ^f   Nieminen, Markku S ^g   Omvik, Per ^d   Dahlöf, Björn ^h   Devereux, Richard B ^c   Wachtell, Kristian ^a,c,i  

^a Rigshospitalet   (Denmark)

^b ODENSE UNIVERSITY HOSPITAL   (Denmark)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

^d UNIVERSITY OF BERGEN   (Norway)

^e HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^f UMEÅ UNIVERSITY   (Sweden)

^g HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^h SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

ⁱ GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

blood pressure; hemodynamics; hypertension; left ventricular hypertrophy

Indexed keywords

ATENOLOL; LOSARTAN;

ADULT; AGED; ANKLE BRACHIAL INDEX; ANTIHYPERTENSIVE THERAPY; ARTERIAL STIFFNESS; ARTERY DIAMETER; ARTICLE; BLOOD PRESSURE MEASUREMENT; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DOUBLE BLIND PROCEDURE; ECHOCARDIOGRAPHY; FEMALE; HEART HEMODYNAMICS; HEART INDEX; HEART RATE; HEART STROKE VOLUME; HIGH RISK PATIENT; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MEAN ARTERIAL PRESSURE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PULSE PRESSURE; RANDOMIZED CONTROLLED TRIAL; VASCULAR RESISTANCE;

AGED; ANTIHYPERTENSIVE AGENTS; ATENOLOL; BLOOD PRESSURE; FEMALE; HEMODYNAMICS; HUMANS; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; LOSARTAN; MALE; MIDDLE AGED;

EID: 84865271304     PISSN: 08957061     EISSN: 19417225     Source Type: Journal    
DOI: 10.1038/ajh.2012.81     Document Type: Article

References (30)

1. Dahlöf B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, Fyhrquist F, Ibsen H, Kristiansson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359:995-1003.
2. Wachtell K, Lehto M, Gerdts E, Olsen MH, Hornestam B, Dahlöf B, Ibsen H, Julius S, Kjeldsen SE, Lindholm LH, Nieminen MS, Devereux RB. Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study. J Am Coll Cardiol 2005; 45:712-719.
3. Devereux RB, Dahlöf B, Gerdts E, Boman K, Nieminen MS, Papademetriou V, Rokkedal J, Harris KE, Edelman JM, Wachtell K. Regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) trial. Circulation 2004; 110:1456-1462.
4. Lindholm LH, Dahlöf B, Edelman JM, Ibsen H, Borch-Johnsen K, Olsen MH, Snapinn S, Wachtell K; LIFE study group. Effect of losartan on sudden cardiac death in people with diabetes: data from the LIFE study. Lancet 2003; 362:619-620.
5. Mancia G, Zanchetti A, Agabiti-Rosei E, Benemio G, De Cesaris R, Fogari R, Pessina A, Porcellati C, Rappelli A, Salvetti A, Trimarco B, Agebiti-Rosei E, Pessino A. Ambulatory blood pressure is superior to clinic blood pressure in predicting treatment-induced regression of left ventricular hypertrophy. SAMPLE Study Group. Study on Ambulatory Monitoring of Blood Pressure and Lisinopril Evaluation. Circulation 1997; 95:1464-1470.
6. Bang LE, Wiinberg N, Wachtell K, Larsen J, Olsen MH, Tuxen C, Hildebrandt PR, Ibsen H. Losartan versus atenolol on 24-hour ambulatory blood pressure. A LIFE substudy. Blood Press 2007; 16:392-397.
7. Williams B, Lacy PS, Thom SM, Cruickshank K, Stanton A, Collier D, Hughes AD, Thurston H, O'Rourke M; CAFE Investigators; Anglo-Scandinavian Cardiac Outcomes Trial Investigators; CAFE Steering Committee and Writing Committee. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation 2006; 113:1213-1225.
8. Oparil S, Izzo JL Jr. Pulsology rediscovered: commentary on the Conduit Artery Function Evaluation (CAFE) study. Circulation 2006; 113:1162-1163.
9. Dahlöf B, Devereux R, de Faire U, Fyhrquist F, Hedner T, Ibsen H, Julius S, Kjeldsen S, Kristianson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H. The Losartan Intervention For Endpoint reduction (LIFE) in Hypertension study: rationale, design, and methods. The LIFE Study Group. Am J Hypertens 1997; 10:705-713.
10. Dahlöf B, Devereux RB, Julius S, Kjeldsen SE, Beevers G, de Faire U, Fyhrquist F, Hedner T, Ibsen H, Kristianson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H. Characteristics of 9194 patients with left ventricular hypertrophy: the LIFE study. Losartan Intervention For Endpoint Reduction in Hypertension. Hypertension 1998; 32:989-997.
11. Palmieri V, Dahlöf B, DeQuattro V, Sharpe N, Bella JN, de Simone G, Paranicas M, Fishman D, Devereux RB. Reliability of echocardiographic assessment of left ventricular structure and function: the PRESERVE study. Prospective Randomized Study Evaluating Regression of Ventricular Enlargement. J Am Coll Cardiol 1999; 34:1625-1632.
12. Sahn DJ, DeMaria A, Kisslo J, Weyman A. Recommendations regarding quantitation in M-mode echocardiography: results of a survey of echocardiographic measurements. Circulation 1978; 58:1072-1083.
13. Schiller NB, Shah PM, Crawford M, DeMaria A, Devereux R, Feigenbaum H, Gutgesell H, Reichek N, Sahn D, Schnittger I. Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms. J Am Soc Echocardiogr 1989; 2:358-367.
14. Dubin J, Wallerson DC, Cody RJ, Devereux RB. Comparative accuracy of Doppler echocardiographic methods for clinical stroke volume determination. Am Heart J 1990; 120:116-123.
15. Randall OS, Westerhof N, van den Bos GC, Alexander B. Reliability of stroke volume to pulse pressure ratio for estimating and detecting changes in arterial compliance. J Hypertens Suppl 1986; 4:S293-S296.
16. Wachtell K, Palmieri V, Olsen MH, Gerdts E, Papademetriou V, Nieminen MS, Smith G, Dahlöf B, Aurigemma G P, Devereux RB. Change in systolic left ventricular performance after 3 years of antihypertensive treatment: the Losartan Intervention for Endpoint (LIFE) Study. Circulation 2002; 106:227-232.
17. Wachtell K, Bella JN, Rokkedal J, Palmieri V, Papademetriou V, Dahlöf B, Aalto T, Gerdts E, Devereux RB. Change in diastolic left ventricular filling after one year of antihypertensive treatment: The Losartan Intervention For Endpoint Reduction in Hypertension (LIFE) Study. Circulation 2002; 105:1071-1076.
18. Omvik P, Gerdts E, Myking OL, Lund-Johansen P. Long-term central hemodynamic effects at rest and during exercise of losartan in essential hypertension. Am Heart J 2000; 140:624-630.
19. Lund-Johansen P. Haemodynamic long-term effects of a new beta-adrenoceptor blocking drug, atenolol (ICI 66082), in essential hypertension. Br J Clin Pharmacol 1976; 3:445-451.
20. Protogerou A, Blacher J, Stergiou GS, Achimastos A, Safar ME. Blood pressure response under chronic antihypertensive drug therapy: the role of aortic stiffness in the REASON (Preterax in Regression of Arterial Stiffness in a Controlled DoubleBlind) study. J Am Coll Cardiol 2009; 53:445-451.
21. Bella JN, Roman MJ, Wachtell K, Gerdts E, Nieminen MS, Boman K, Dahlof B, Devereux RB. Impact of atenolol versus losartan-based treatment on aortic root dilatation in hypertension: the LIFE study. Circulation 2006; 114(Abstract-SuppI II):II-360.
22. Gerdts E, Franklin S, Rieck A, Papademetriou V, Wachtell K, Nieminen M, Dahlöf B, Devereux RB. Pulse pressure, left ventricular function and cardiovascular events during antihypertensive treatment (the LIFE study). Blood Press 2009; 18:180-186.
23. Gerdts E, Cramariuc D, de Simone G, Wachtell K, Dahlöf B, Devereux RB. Impact of left ventricular geometry on prognosis in hypertensive patients with left ventricular hypertrophy (the LIFE study). Eur J Echocardiogr 2008; 9:809-815.
24. Lønnebakken MT, Gerdts E, Boman K, Wachtell K, Dahlöf B, Devereux RB. In-treatment stroke volume predicts cardiovascular risk in hypertension. J Hypertens 2011; 29:1508-1514.
25. Segers P, Stergiopulos N, Westerhof N. Quantification of the contribution of cardiac and arterial remodeling to hypertension. Hypertension 2000; 36:760-765.
26. Böhm M, Swedberg K, Komajda M, Borer JS, Ford I, Dubost-Brama A, Lerebours G, Tavazzi L. Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial. Lancet 2010; 376:886-894.
27. Wachtell K, Gerdts E, Palmieri V, Olsen MH, Nieminen MS, Papademetriou V, Boman K, Dahlöf B, Aurigemma G P, Rokkedal JE, Devereux RB. In-treatment midwall and endocardial fractional shortening predict cardiovascular outcome in hypertensive patients with preserved baseline systolic ventricular function: the Losartan Intervention For Endpoint reduction study. J Hypertens 2010; 28:1541-1546.
28. Wachtell K, Palmieri V, Gerdts E, Bella JN, Aurigemma G P, Papademetriou V, Dahlöf B, Aalto T, Ibsen H, Rokkedal JE, Devereux RB. Prognostic significance of left ventricular diastolic dysfunction in patients with left ventricular hypertrophy and systemic hypertension (the LIFE Study). Am J Cardiol 2010; 106:999-1005.
29. Okin PM, Kjeldsen SE, Julius S, Hille DA, Dahlöf B, Edelman JM, Devereux RB. All-cause and cardiovascular mortality in relation to changing heart rate during treatment of hypertensive patients with electrocardiographic left ventricular hypertrophy. Eur Heart J 2010; 31:2271-2279.
30. Remington JW, Noback CR. Volume elasticity characteristics of the human aorta and prediction of the stroke volume from the pressure pulse. Am J Physiol 1948; 153:298-308.